The product

A natural treatment for inflammatory disorders

TLA Gut is the first family of TLA column devices, developed to treat patients with ulcerative colitis. The TLA Gut column contains the TECK/CCL25 chemokine, which selectively binds to the CCR9 receptor on the surface of activated immune cells. In the scientific community, the CCL25/CCR9 axis has been attributed a fundamental role in chronic intestinal inflammation, and has been exploited through pharmaceutical blockade in several large clinical trials.

The safety and clinical effect of TLA Gut in ulcerative colitis was addressed in the TLA-001 proof-of-concept study.

Peripheral blood is drawn from a vein in the arm of the patient

The blood is perfused over to the TLA device with the aid of a hemoperfusion machine

In the column, immune cells that carry the chemokine-specific surface marker (chemokine receptor) that matches the chemokine attached to the in-column matrix are retained

All other blood cells and blood fluid passes freely through the column

Untouched cells and blood fluid are returned to the other arm of the patient

The potential to treat other inflammatory disorders

Currently, some 50 chemokines have been identified, that play different roles in different inflammatory diseases. The design and manufacturing process of the TLA column have been developed to allow for easy replacement of the chemokine. In this way, the specific type of inflammation in a specific patient group may be targeted by simply changing the chemokine.

A major focus of TLA’s Research and Development program is to identify and characterize disease mechanisms in various patient groups with inflammatory disorders, to be potentially used in a TLA device.

TLA Gut is the first TLA column device, developed to suppress inflammation in patients with ulcerative colitis. The clinical pipeline includes evaluation of TLA Gut in pediatric patients with inflammatory bowel disease (IBD), as well as demonstrating proof-of-concept of the second TLA column, targeting patients with acute lateral sclerosis (ALS).